ANXA1 and bronchopulmonary dysplasia: ANXA1, a protease inhibitor, also known to have innate immune properties, which was decreased in the PTlow group but not in the BPD group, has been implicated in early lung injury in neonatal mouse models36, and also in proteomic studies of EBC from adults with pneumonia31.